source
- Novo Nordisk files lawsuit against Eli Lilly over allegedly deceptive GLP-1 dose adsNovo Nordisk has initiated legal action against Eli Lilly in a U.S. court, alleging that Lilly's recent advertisements misrepresent the dosing of GLP-1 obesity treatments. The company says the ads…
- Rare disease drugmakers brace for potential Trump administration price cuts amid GOP push on health‑care fraudRare disease drugmakers are watching the Trump administration closely as proposals emerge that could force lower prices for their specialty therapies. The companies are exploring strategies to miti…